**Assessing the Value Contribution of Bimekizumab for the Treatment of Moderate-to-Severe Psoriasis Using a Multidisciplinary Reflective Multi-Criteria Decision Analysis**

**Authors**: Néboa Zozaya1,2, Fernando Abdalla1, Santiago Alfonso Zamora3, Jesús Balea Filgueiras4, José Manuel Carrascosa Carrillo5, Olga Delgado Sánchez6, Francisco Dolz Sinisterra7, Antonio García-Ruiz8, Pedro Herranz Pinto9, Antonio Manfredi3, José Martínez Olmos10, Paloma Morales de los Ríos Luna11, Lluis Puig12, Sandra Ros13, Álvaro Hidalgo14,15

**Affiliations**: 1Department of Health Economics, Weber, Madrid, Spain; 2Department of Quantitative Methods in Economics and Management, University Las Palmas de Gran Canaria. Las Palmas, Spain; 3Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain; 4Department of Pharmacy, Ferrol University Hospital Complex, La Coruña, Spain; 5Department of Dermatology, Germans Trias i Pujol University Hospital, Badalona, Spain; 6Department of Management, Spanish Society of Hospital Pharmacy (SEFH). Department of Pharmacy, Son Espases University Hospital, Illes Balears, Spain; 7Department of Management, Doctor Peset University Hospital, Valencia, Spain; 8Health Economics and Rational Use of Medicines. Department of Pharmacology and Clinical Therapeutics. Biomedical Research Institute of Malaga (IBIMA). University of Malaga, Malaga, Spain; 9Department of Dermatology, La Paz University Hospital, Madrid, Spain; 10Andalusian Public Health School (EASP), Granada, Spain; 11Department of Nursing, Gregorio Marañón University Hospital, Madrid, Spain; 12Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; 13Pshycologist, Department of Dermatology, Rheumatology and Cardiac Transplantation, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 14Weber Foundation, Madrid, Spain; 15Department of Economic Analysis and Finances, University of Castilla-La Mancha. Toledo, Spain

**SUPPLEMENTARY FILE 2: WEIGHTS, SCORES AND VALUE ESTIMATES**

***overall and by subgroup***

**List of tables**

|  |
| --- |
| [Table (S2).1: Weights, 100-points distribution, overall (n=12) and by subgroup, mean ± standard deviation (median) 3](#_Toc89097195)  [Table (S2).2: Scores, overall (n=12), mean ± standard deviation (median) 4](#_Toc89097196)  [Table (S2).3: Scores, healthcare professionals (n=5), mean ± standard deviation (median) 5](#_Toc89097197)  [Table (S2).4: Scores, patients (n=2), mean ± standard deviation (median) 6](#_Toc89097198)  [Table (S2).5: Scores, managers (n=5), mean ± standard deviation (median) 7](#_Toc89097199)  [Table (S2).6: Value estimates, 100-points distribution, overall (n=12), mean ± standard deviation 8](#_Toc89097200)  [Table (S2).7: Value estimates, 100-points distribution, healthcare professionals (n=5), mean ± standard deviation 9](#_Toc89097201)  [Table (S2).8: Value estimates, 100-points distribution, patients (n=2), mean ± standard deviation 10](#_Toc89097202)  [Table (S2).9: Value estimates, 100-points distribution, managers (n=5), mean ± standard deviation 11](#_Toc89097203) |

# **1. Weights**

**Table (S2).1: Weights, 100-points distribution, overall (n=12) and by subgroup, mean ± standard deviation (median)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Criteria | Overall (n=12) | HC professionals (n=5) | Patients (n=2) | Managers (n=5) |
| Need for the intervention | | | | |
| Disease severity | 8.4 ± 3.4 (9.0) | 9.4 ± 2.2 (10.0) | 8.0 ± 2.8 (8.0) | 7.6 ± 4.8 (6.0) |
| Size of affected population | 3.7 ± 1.9 (4.0) | 3.4 ± 2.1 (4.0) | 4.0 ± 2.8 (4.0) | 3.8 ± 1.8 (4.0) |
| Unmet needs | 7.7 ± 2.2 (7.5) | 7.6 ± 2.6 (8.0) | 9.0 ± 2.8 (9.0) | 7.2 ± 1.9 (7.0) |
| Outcomes of the intervention | | | | |
| Level of clearance | 11.3 ± 6.6 (10.0) | 11.2 ± 2.4 (10.0) | 7.0 ± 4.2 (7.0) | 13.0 ± 9.7 (9.0) |
| Rapidity of clearance | 4.9 ± 2.6 (5.0) | 5.2 ± 2.9 (5.0) | 4.5 ± 3.5 (4.5) | 4.8 ± 2.7 (5.0) |
| Persistence of clearance | 9.8 ± 2.2 (9.5) | 10.2 ± 3.3 (9.0) | 9.5 ± 2.1 (9.5) | 9.6 ± 1.1 (10.0) |
| Safety / tolerability | 9.8 ± 2.2 (9.0) | 11.2 ± 2.8 (12.0) | 8.0 ± 0.0 (8.0) | 9.0 ± 1.0 (9.0) |
| Patient reported outcomes | 7.5 ± 3.1 (7.5) | 7.6 ± 3.9 (9.0) | 8.5 ± 3.5 (8.5) | 7.0 ± 2.7 (7.0) |
| Type of benefit of the intervention | | | | |
| Type of therapeutic benefit | 7.6 ± 3.4 (8.0) | 6.2 ± 4.4 (6.0) | 8.5 ± 0.7 (8.5) | 8.6 ± 3.0 (8.0) |
| Consistency of the effect | 6.2 ± 3.2 (7.5) | 4.4 ± 3.2 (4.0) | 9.0 ± 1.4 (9.0) | 6.8 ± 3.1 (8.0) |
| Economic consequences of the intervention | | | | |
| Cost of intervention | 5.8 ± 3.1 (5.5) | 6.6 ± 4.2 (6.0) | 5.0 ± 1.4 (5.0) | 5.4 ± 2.6 (5.0) |
| Impact on other direct costs | 3.3 ± 1.8 (3.5) | 2.6 ± 2.1 (3.0) | 4.5 ± 0.7 (4.5) | 3.4 ± 1.7 (3.0) |
| Impact on indirect costs | 3.5 ± 2.5 (3.0) | 3.2 ± 2.9 (3.0) | 3.5 ± 0.7 (3.5) | 3.8 ± 3.0 (2.0) |
| Knowledge about the intervention | | | | |
| Quality of evidence | 6.0 ± 1.7 (6.5) | 6.1 ± 2.1 (7.0) | 6.0 ± 2.8 (6.0) | 6.0 ± 1.0 (6.0) |
| Expert consensus / CPG | 4.6 ± 1.8 (4.5) | 5.1 ± 2.4 (5.0) | 5.0 ± 1.4 (5.0) | 4.0 ± 1.2 (4.0) |
| Total | **100.0 ± 0.0 (100.0)** | **100.0 ± 0.0 (100.0)** | **100.0 ± 0.0 (100.0)** | **100.0 ± 0.0 (100.0)** |

HC: healthcare; Healthcare professionals: dermatologists, nurse and psychologist. Managers: healthcare managers, hospital pharmacist, health economist and politician. CPG: clinical practice guidelines

# **2. Scores**

**Table (S2).2: Scores, overall (n=12), mean ± standard deviation (median)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Criteria | BKZ vs. PBO | BKZ vs. ADA | BKZ vs. UST | BKZ vs. SEC | BKZ vs. IXE | BKZ vs. RIS |
| Need for the intervention | | | | | | |
| Disease severity | 3.8 ± 0.5 (4.0) | | | | | |
| Size of affected population | 3.0 ± 0.4 (3.0) | | | | | |
| Unmet needs | 3.5 ± 0.9 (4.0) | | | | | |
| Outcomes of the intervention | | | | | | |
| Level of clearance | 4.8 ± 0.4 (5.0) | 3.6 ± 0.8 (4.0) | 3.3 ± 0.7 (3.0) | 2.7 ± 1.0 (2.0) | 2.1 ± 1.0 (2.0) | 2.2 ± 1.1 (2.0) |
| Rapidity of clearance | 4.8 ± 0.6 (5.0) | 3.3 ± 0.7 (3.0) | 3.8 ± 0.6 (4.0) | 2.3 ± 0.8 (2.5) | 2.1 ± 0.8 (2.0) | 3.4 ± 0.8 (4.0) |
| Persistence of clearance | 4.8 ± 0.6 (5.0) | 3.5 ± 0.5 (3.5) | 2.8 ± 1.4 (3.0) | 2.7 ± 0.7 (3.0) | 2.3 ± 1.4 (3.0) | 2.2 ± 1.6 (3.0) |
| Safety / tolerability | -0.3 ± 2.6 (-1.0) | 1.7 ± 1.6 (2.0) | 0.6 ± 1.6 (0.5) | 0.4 ± 1.6 (0.0) | 0.5 ± 1.1 (0.0) | -0.1 ± 1.5 (-0.5) |
| Patient reported outcomes | 4.6 ± 0.7 (5.0) | 2.8 ± 1.0 (3.0) | 1.9 ± 1.2 (2.0) | 1.8 ± 1.4 (2.0) | 1.3 ± 1.2 (1.0) | 0.8 ± 1.3 (1.0) |
| Type of benefit for the intervention | | | | | | |
| Type of therapeutic benefit | 3.6 ± 0.7 (4.0) | | | | | |
| Consistency of the effect | 4.5 ± 0.8 (5.0) | 2.2 ± 1.6 (3.0) | 2.2 ± 1.3 (2.0) | 1.0 ± 1.2 (1.0) | 0.9 ± 1.6 (0.5) | 1.6 ± 1.2 (1.0) |
| Economic consequences of the intervention | | | | | | |
| Cost of intervention | -3.8 ± 1.9 (-5.0) | -2.3 ± 1.9 (-2.0) | -0.5 ± 1.3 (-1.0) | 0.1 ± 0.3 (0.0) | -0.3 ± 0.8 (0.0) | 0.8 ± 0.8 (1.0) |
| Impact on other direct costs | 3.1 ± 1.6 (3.5) | 1.2 ± 0.8 (1.0) | 1.2 ± 1.2 (1.0) | 0.8 ± 0.6 (1.0) | 0.8 ± 0.8 (1.0) | 0.8 ± 0.8 (1.0) |
| Impact on indirect costs | 3.7 ± 1.0 (3.5) | 1.4 ± 1.0 (1.0) | 1.4 ± 0.9 (1.0) | 0.9 ± 0.7 (1.0) | 0.8 ± 0.6 (1.0) | 0.8 ± 0.6 (1.0) |
| Knowledge about the intervention | | | | | | |
| Quality of evidence | 4.3 ± 1.0 (4.5) | 4.0 ± 1.1 (4.0) | 4.1 ± 1.0 (4.0) | 4.0 ± 1.2 (4.5) | 2.8 ± 1.4 (2.0) | 2.8 ± 1.4 (2.0) |
| Expert consensus / CPG | 4.3 ± 1.2 (5.0) | 1.9 ± 2.0 (2.0) | 1.7 ± 1.9 (2.0) | 1.3 ± 1.6 (2.0) | 0.8 ± 1.1 (1.0) | 1.1 ± 1.4 (1.0) |

BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab. CPG: clinical practice guidelines

**Table (S2).3: Scores, healthcare professionals (n=5), mean ± standard deviation (median)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Criteria | BKZ vs. PBO | BKZ vs. ADA | BKZ vs. UST | BKZ vs. SEC | BKZ vs. IXE | BKZ vs. RIS |
| Need for the intervention | | | | | | |
| Disease severity | 3.8 ± 0.4 (4.0) | | | | | |
| Size of affected population | 3.2 ± 0.4 (3.0) | | | | | |
| Unmet needs | 3.2 ± 1.3 (3.0) | | | | | |
| Outcomes of the intervention | | | | | | |
| Level of clearance | 5.0 ± 0.0 (5.0) | 3.8 ± 0.8 (4.0) | 3.2 ± 0.8 (3.0) | 2.4 ± 0.5 (2.0) | 1.6 ± 0.9 (1.0) | 1.4 ± 1.1 (1.0) |
| Rapidity of clearance | 5.0 ± 0.0 (5.0) | 3.4 ± 0.9 (3.0) | 4.0 ± 0.7 (4.0) | 1.8 ± 0.8 (2.0) | 1.6 ± 0.9 (1.0) | 3.2 ± 0.8 (3.0) |
| Persistence of clearance | 5.0 ± 0.0 (5.0) | 3.4 ± 0.5 (3.0) | 2.0 ± 1.9 (3.0) | 2.2 ± 0.4 (2.0) | 1.2 ± 1.3 (1.0) | 0.8 ± 1.6 (0.0) |
| Safety / tolerability | -1.4 ± 1.5 (-2.0) | 2.0 ± 1.9 (2.0) | 0.0 ± 2.0 (-1.0) | -0.4 ± 0.9 (-1.0) | 0.0 ± 0.7 (0.0) | -0.6 ± 1.7 (-1.0) |
| Patient reported outcomes | 5.0 ± 0.0 (5.0) | 3.0 ± 1.2 (3.0) | 1.8 ± 1.6 (2.0) | 1.4 ± 0.9 (2.0) | 1.2 ± 0.4 (1.0) | 0.2 ± 0.8 (0.0) |
| Type of benefit for the intervention | | | | | | |
| Type of therapeutic benefit | 3.8 ± 0.4 (4.0) | | | | | |
| Consistency of the effect | 5.0 ± 0.0 (5.0) | 2.0 ± 2.2 (3.0) | 2.2 ± 1.9 (3.0) | 0.4 ± 1.7 (0.0) | 0.2 ± 1.1 (0.0) | 1.6 ± 1.7 (2.0) |
| Economic consequences of the intervention | | | | | | |
| Cost of intervention | -5.0 ± 0.0 (-5.0) | -3.4 ± 1.8 (-4.0) | 0.0 ± 1.6 (0.0) | 0.0 ± 0.0 (0.0) | -0.2 ± 0.4 (0.0) | 0.4 ± 0.5 (0.0) |
| Impact on other direct costs | 3.4 ± 1.5 (4.0) | 1.0 ± 1.0 (1.0) | 1.0 ± 1.2 (1.0) | 0.6 ± 0.9 (0.0) | 0.4 ± 0.9 (0.0) | 0.6 ± 0.9 (0.0) |
| Impact on indirect costs | 3.8 ± 1.3 (4.0) | 1.8 ± 0.8 (2.0) | 1.6 ± 0.9 (1.0) | 0.8 ± 0.8 (1.0) | 0.4 ± 0.5 (0.0) | 0.6 ± 0.5 (1.0) |
| Knowledge about the intervention | | | | | | |
| Quality of evidence | 4.4 ± 1.3 (5.0) | 4.2 ± 1.3 (5.0) | 4.4 ± 0.9 (5.0) | 4.0 ± 1.4 (5.0) | 2.4 ± 0.9 (2.0) | 2.4 ± 0.9 (2.0) |
| Expert consensus / CPG | 4.6 ± 0.9 (5.0) | 1.6 ± 2.6 (2.0) | 1.4 ± 2.4 (2.0) | 1.6 ± 2.1 (2.0) | 0.8 ± 1.3 (0.0) | 1.2 ± 1.6 (1.0) |

Healthcare professionals: dermatologists, nurse and psychologist. BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab. CPG: clinical practice guidelines

**Table (S2).4: Scores, patients (n=2), mean ± standard deviation (median)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Criteria | BKZ vs. PBO | BKZ vs. ADA | BKZ vs. UST | BKZ vs. SEC | BKZ vs. IXE | BKZ vs. RIS |
| Need for the intervention | | | | | | |
| Disease severity | 4.0 ± 0.0 (4.0) | | | | | |
| Size of affected population | 3.0 ± 0.0 (3.0) | | | | | |
| Unmet needs | 4.0 ± 0.0 (4.0) | | | | | |
| Outcomes of the intervention | | | | | | |
| Level of clearance | 5.0 ± 0.0 (5.0) | 3.0 ± 1.4 (3.0) | 3.5 ± 0.7 (3.5) | 3.5 ± 2.1 (3.5) | 2.0 ± 0.0 (2.0) | 2.5 ± 0.7 (2.5) |
| Rapidity of clearance | 5.0 ± 0.0 (5.0) | 3.0 ± 0.0 (3.0) | 4.0 ± 0.0 (4.0) | 3.0 ± 0.0 (3.0) | 2.5 ± 0.7 (2.5) | 3.5 ± 0.7 (3.5) |
| Persistence of clearance | 5.0 ± 0.0 (5.0) | 3.5 ± 0.7 (3.5) | 4.0 ± 0.0 (4.0) | 3.0 ± 0.0 (3.0) | 3.5 ± 0.7 (3.5) | 3.5 ± 0.7 (3.5) |
| Safety / tolerability | 2.0 ± 4.2 (2.0) | 1.5 ± 0.7 (1.5) | 1.5 ± 0.7 (1.5) | 2.0 ± 0.0 (2.0) | 1.5 ± 0.7 (1.5) | 1.5 ± 0.7 (1.5) |
| Patient reported outcomes | 4.5 ± 0.7 (4.5) | 3.0 ± 0.0 (3.0) | 2.5 ± 0.7 (2.5) | 2.0 ± 0.0 (2.0) | 2.0 ± 0.0 (2.0) | 2.0 ± 0.0 (2.0) |
| Type of benefit for the intervention | | | | | | |
| Type of therapeutic benefit | 4.0 ± 0.0 (4.0) | | | | | |
| Consistency of the effect | 4.5 ± 0.7 (4.5) | 1.0 ± 0.0 (1.0) | 2.5 ± 0.7 (2.5) | 1.0 ± 0.0 (1.0) | 2.5 ± 0.7 (2.5) | 2.0 ± 1.4 (2.0) |
| Economic consequences of the intervention | | | | | | |
| Cost of intervention | -2.5 ± 0.7 (-2.5) | -0.5 ± 0.7 (-0.5) | -0.5 ± 0.7 (-0.5) | 0.0 ± 0.0 (0.0) | -0.5 ± 0.7 (-0.5) | 0.5 ± 0.7 (0.5) |
| Impact on other direct costs | 4.5 ± 0.7 (4.5) | 1.5 ± 0.7 (1.5) | 2.5 ± 2.1 (2.5) | 1.0 ± 0.0 (1.0) | 1.5 ± 0.7 (1.5) | 1.5 ± 0.7 (1.5) |
| Impact on indirect costs | 4.5 ± 0.7 (4.5) | 1.5 ± 2.1 (1.5) | 2.5 ± 0.7 (2.5) | 1.5 ± 0.7 (1.5) | 1.5 ± 0.7 (1.5) | 1.5 ± 0.7 (1.5) |
| Knowledge about the intervention | | | | | | |
| Quality of evidence | 4.5 ± 0.7 (4.5) | 4.5 ± 0.7 (4.5) | 4.5 ± 0.7 (4.5) | 4.5 ± 0.7 (4.5) | 4.0 ± 1.4 (4.0) | 4.0 ± 1.4 (4.0) |
| Expert consensus / CPG | 5.0 ± 0.0 (5.0) | 3.0 ± 1.4 (3.0) | 3.0 ± 1.4 (3.0) | 1.5 ± 0.7 (1.5) | 1.5 ± 0.7 (1.5) | 1.5 ± 0.7 (1.5) |

BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab. CPG: clinical practice guidelines

**Table (S2).5: Scores, managers (n=5), mean ± standard deviation (median)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Criteria | BKZ vs. PBO | BKZ vs. ADA | BKZ vs. UST | BKZ vs. SEC | BKZ vs. IXE | BKZ vs. RIS |
| Need for the intervention | | | | | | |
| Disease severity | 3.6 ± 0.5 (4.0) | | | | | |
| Size of affected population | 2.8 ± 0.4 (3.0) | | | | | |
| Unmet needs | 3.6 ± 0.5 (4.0) | | | | | |
| Outcomes of the intervention | | | | | | |
| Level of clearance | 4.6 ± 0.5 (5.0) | 3.6 ± 0.5 (4.0) | 3.4 ± 0.5 (3.0) | 2.6 ± 0.9 (2.0) | 2.6 ± 1.1 (3.0) | 2.8 ± 0.8 (3.0) |
| Rapidity of clearance | 4.6 ± 0.9 (5.0) | 3.4 ± 0.5 (3.0) | 3.6 ± 0.5 (4.0) | 2.6 ± 0.5 (3.0) | 2.4 ± 0.5 (2.0) | 3.6 ± 0.9 (4.0) |
| Persistence of clearance | 4.6 ± 0.9 (5.0) | 3.6 ± 0.5 (4.0) | 3.2 ± 0.4 (3.0) | 3.0 ± 0.7 (3.0) | 3.0 ± 0.7 (3.0) | 3.0 ± 0.7 (3.0) |
| Safety / tolerability | -0.2 ± 2.7 (0.0) | 1.4 ± 1.8 (1.0) | 0.8 ± 1.3 (0.0) | 0.6 ± 1.9 (0.0) | 0.6 ± 1.3 (0.0) | -0.2 ± 1.3 (-1.0) |
| Patient reported outcomes | 4.2 ± 0.8 (4.0) | 2.6 ± 1.1 (3.0) | 1.8 ± 1.1 (2.0) | 1.8 ± 1.8 (2.0) | 1.2 ± 1.8 (0.0) | 1.0 ± 1.6 (1.0) |
| Type of benefit for the intervention | | | | | | |
| Type of therapeutic benefit | 3.2 ± 0.8 (3.0) | | | | | |
| Consistency of the effect | 4.0 ± 1.0 (4.0) | 2.8 ± 0.8 (3.0) | 2.0 ± 0.7 (2.0) | 1.6 ± 0.5 (2.0) | 1.0 ± 1.9 (1.0) | 1.4 ± 0.9 (1.0) |
| Economic consequences of the intervention | | | | | | |
| Cost of intervention | -3.2 ± 2.7 (-5.0) | -1.8 ± 1.8 (-2.0) | -1.0 ± 1.2 (-1.0) | 0.2 ± 0.4 (0.0) | -0.4 ± 1.1 (0.0) | 1.4 ± 0.9 (1.0) |
| Impact on other direct costs | 2.2 ± 1.5 (2.0) | 1.2 ± 0.8 (1.0) | 0.8 ± 0.4 (1.0) | 0.8 ± 0.4 (1.0) | 0.8 ± 0.4 (1.0) | 0.6 ± 0.5 (1.0) |
| Impact on indirect costs | 3.2 ± 0.4 (3.0) | 1.0 ± 0.7 (1.0) | 0.8 ± 0.4 (1.0) | 0.8 ± 0.4 (1.0) | 0.8 ± 0.4 (1.0) | 0.8 ± 0.4 (1.0) |
| Knowledge about the intervention | | | | | | |
| Quality of evidence | 4.0 ± 0.7 (4.0) | 3.6 ± 1.1 (4.0) | 3.6 ± 1.1 (4.0) | 3.8 ± 1.3 (4.0) | 2.6 ± 1.8 (2.0) | 2.6 ± 1.8 (2.0) |
| Expert consensus / CPG | 3.8 ± 1.6 (4.0) | 1.8 ± 1.6 (2.0) | 1.4 ± 1.7 (1.0) | 1.0 ± 1.4 (2.0) | 0.6 ± 1.1 (1.0) | 0.8 ± 1.5 (1.0) |

Managers: healthcare managers, hospital pharmacist, health economist and politician. BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab. CPG: clinical practice guidelines

# **3. Value estimates**

**Table (S2).6: Value estimates, 100-points distribution, overall (n=12), mean ± standard deviation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Criteria | BKZ vs. PBO | BKZ vs. ADA | BKZ vs. UST | BKZ vs. SEC | BKZ vs. IXE | BKZ vs. RIS |
| Need for the intervention | | | | | | |
| Disease severity | 0.063 ± 0.022 | | | | | |
| Size of affected population | 0.022 ± 0.012 | | | | | |
| Unmet needs | 0.055 ± 0.022 | | | | | |
| Outcomes of the intervention | | | | | | |
| Level of clearance | 0.109 ± 0.066 | 0.083 ± 0.055 | 0.075 ± 0.054 | 0.062 ± 0.057 | 0.052 ± 0.061 | 0.052 ± 0.061 |
| Rapidity of clearance | 0.046 ± 0.023 | 0.032 ± 0.015 | 0.037 ± 0.019 | 0.023 ± 0.015 | 0.022 ± 0.016 | 0.033 ± 0.019 |
| Persistence of clearance | 0.095 ± 0.026 | 0.069 ± 0.021 | 0.054 ± 0.028 | 0.052 ± 0.014 | 0.046 ± 0.029 | 0.043 ± 0.032 |
| Safety / tolerability | -0.007 ± 0.047 | 0.033 ± 0.034 | 0.010 ± 0.030 | 0.008 ± 0.030 | 0.009 ± 0.021 | -0.002 ± 0.031 |
| Patient reported outcomes | 0.069 ± 0.032 | 0.043 ± 0.025 | 0.033 ± 0.022 | 0.030 ± 0.028 | 0.021 ± 0.020 | 0.015 ± 0.019 |
| Type of benefit for the intervention | | | | | | |
| Type of therapeutic benefit | 0.054 ± 0.027 | | | | | |
| Consistency of the effect | 0.056 ± 0.032 | 0.024 ± 0.026 | 0.026 ± 0.023 | 0.013 ± 0.018 | 0.015 ± 0.027 | 0.021 ± 0.020 |
| Economic consequences of the intervention | | | | | | |
| Cost of intervention | -0.047 ± 0.035 | -0.032 ± 0.038 | -0.002 ± 0.021 | 0.001 ± 0.002 | -0.004 ± 0.009 | 0.009 ± 0.012 |
| Impact on other direct costs | 0.021 ± 0.017 | 0.009 ± 0.007 | 0.010 ± 0.012 | 0.006 ± 0.006 | 0.007 ± 0.007 | 0.007 ± 0.007 |
| Impact on indirect costs | 0.027 ± 0.023 | 0.011 ± 0.012 | 0.011 ± 0.012 | 0.008 ± 0.009 | 0.006 ± 0.007 | 0.007 ± 0.006 |
| Knowledge about the intervention | | | | | | |
| Quality of evidence | 0.052 ± 0.022 | 0.049 ± 0.022 | 0.050 ± 0.021 | 0.048 ± 0.021 | 0.033 ± 0.021 | 0.033 ± 0.021 |
| Expert consensus / CPG | 0.040 ± 0.021 | 0.019 ± 0.024 | 0.017 ± 0.023 | 0.014 ± 0.021 | 0.009 ± 0.015 | 0.012 ± 0.019 |
| Total | **0.654 ± 0.102** | **0.532 ± 0.088** | **0.512 ± 0.100** | **0.457 ± 0.089** | **0.407 ± 0.122** | **0.421 ± 0.133** |

BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab. CPG: clinical practice guidelines

**Table (S2).7: Value estimates, 100-points distribution, healthcare professionals (n=5), mean ± standard deviation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Criteria | BKZ vs. PBO | BKZ vs. ADA | BKZ vs. UST | BKZ vs. SEC | BKZ vs. IXE | BKZ vs. RIS |
| Need for the intervention | | | | | | |
| Disease severity | 0.070 ± 0.013 | | | | | |
| Size of affected population | 0.022 ± 0.015 | | | | | |
| Unmet needs | 0.049 ± 0.024 | | | | | |
| Outcomes of the intervention | | | | | | |
| Level of clearance | 0.112 ± 0.024 | 0.084 ± 0.017 | 0.069 ± 0.009 | 0.052 ± 0.009 | 0.034 ± 0.014 | 0.029 ± 0.022 |
| Rapidity of clearance | 0.052 ± 0.029 | 0.034 ± 0.016 | 0.042 ± 0.024 | 0.018 ± 0.013 | 0.017 ± 0.014 | 0.034 ± 0.026 |
| Persistence of clearance | 0.102 ± 0.033 | 0.070 ± 0.030 | 0.037 ± 0.036 | 0.044 ± 0.012 | 0.025 ± 0.030 | 0.018 ± 0.036 |
| Safety / tolerability | -0.028 ± 0.031 | 0.043 ± 0.042 | -0.002 ± 0.039 | -0.007 ± 0.019 | 0.000 ± 0.017 | -0.012 ± 0.038 |
| Patient reported outcomes | 0.076 ± 0.039 | 0.044 ± 0.030 | 0.032 ± 0.024 | 0.026 ± 0.021 | 0.019 ± 0.014 | 0.006 ± 0.012 |
| Type of benefit for the intervention | | | | | | |
| Type of therapeutic benefit | 0.048 ± 0.036 | | | | | |
| Consistency of the effect | 0.044 ± 0.032 | 0.010 ± 0.028 | 0.014 ± 0.023 | 0.000 ± 0.016 | 0.000 ± 0.011 | 0.015 ± 0.016 |
| Economic consequences of the intervention | | | | | | |
| Cost of intervention | -0.066 ± 0.042 | -0.054 ± 0.050 | 0.010 ± 0.026 | 0.000 ± 0.000 | -0.001 ± 0.003 | 0.002 ± 0.003 |
| Impact on other direct costs | 0.018 ± 0.018 | 0.008 ± 0.008 | 0.009 ± 0.012 | 0.005 ± 0.009 | 0.004 ± 0.009 | 0.006 ± 0.009 |
| Impact on indirect costs | 0.026 ± 0.029 | 0.011 ± 0.012 | 0.012 ± 0.017 | 0.007 ± 0.012 | 0.003 ± 0.006 | 0.005 ± 0.006 |
| Knowledge about the intervention | | | | | | |
| Quality of evidence | 0.054 ± 0.027 | 0.051 ± 0.026 | 0.053 ± 0.023 | 0.048 ± 0.025 | 0.026 ± 0.005 | 0.026 ± 0.005 |
| Expert consensus / CPG | 0.047 ± 0.026 | 0.022 ± 0.036 | 0.020 ± 0.033 | 0.022 ± 0.031 | 0.012 ± 0.021 | 0.017 ± 0.027 |
| Total | **0.626 ± 0.106** | **0.512 ± 0.115** | **0.485 ± 0.133** | **0.405 ± 0.082** | **0.328 ± 0.108** | **0.337 ± 0.154** |

Healthcare professionals: dermatologists, nurse and psychologist. BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab. CPG: clinical practice guidelines

**Table (S2).8: Value estimates, 100-points distribution, patients (n=2), mean ± standard deviation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Criteria | BKZ vs. PBO | BKZ vs. ADA | BKZ vs. UST | BKZ vs. SEC | BKZ vs. IXE | BKZ vs. RIS |
| Need for the intervention | | | | | | |
| Disease severity | 0.064 ± 0.023 | | | | | |
| Size of affected population | 0.024 ± 0.017 | | | | | |
| Unmet needs | 0.072 ± 0.023 | | | | | |
| Outcomes of the intervention | | | | | | |
| Level of clearance | 0.070 ± 0.042 | 0.048 ± 0.045 | 0.046 ± 0.020 | 0.040 ± 0.000 | 0.028 ± 0.017 | 0.032 ± 0.011 |
| Rapidity of clearance | 0.045 ± 0.035 | 0.027 ± 0.021 | 0.036 ± 0.028 | 0.027 ± 0.021 | 0.025 ± 0.024 | 0.034 ± 0.031 |
| Persistence of clearance | 0.095 ± 0.021 | 0.065 ± 0.001 | 0.076 ± 0.017 | 0.057 ± 0.013 | 0.068 ± 0.028 | 0.068 ± 0.028 |
| Safety / tolerability | 0.032 ± 0.068 | 0.024 ± 0.011 | 0.024 ± 0.011 | 0.032 ± 0.000 | 0.024 ± 0.011 | 0.024 ± 0.011 |
| Patient reported outcomes | 0.079 ± 0.044 | 0.051 ± 0.021 | 0.045 ± 0.030 | 0.050 ± 0.054 | 0.034 ± 0.014 | 0.034 ± 0.014 |
| Type of benefit for the intervention | | | | | | |
| Type of therapeutic benefit | 0.068 ± 0.006 | | | | | |
| Consistency of the effect | 0.082 ± 0.025 | 0.018 ± 0.003 | 0.046 ± 0.020 | 0.018 ± 0.003 | 0.046 ± 0.020 | 0.038 ± 0.031 |
| Economic consequences of the intervention | | | | | | |
| Cost of intervention | -0.026 ± 0.014 | -0.006 ± 0.008 | -0.006 ± 0.008 | 0.000 ± 0.000 | -0.006 ± 0.008 | 0.006 ± 0.008 |
| Impact on other direct costs | 0.041 ± 0.013 | 0.013 ± 0.004 | 0.024 ± 0.023 | 0.009 ± 0.001 | 0.014 ± 0.008 | 0.014 ± 0.008 |
| Impact on indirect costs | 0.031 ± 0.001 | 0.012 ± 0.017 | 0.018 ± 0.008 | 0.011 ± 0.007 | 0.011 ± 0.007 | 0.010 ± 0.003 |
| Knowledge about the intervention | | | | | | |
| Quality of evidence | 0.056 ± 0.034 | 0.056 ± 0.034 | 0.056 ± 0.034 | 0.056 ± 0.034 | 0.052 ± 0.040 | 0.052 ± 0.040 |
| Expert consensus / CPG | 0.050 ± 0.014 | 0.028 ± 0.006 | 0.028 ± 0.006 | 0.014 ± 0.003 | 0.014 ± 0.003 | 0.014 ± 0.003 |
| Total | **0.783 ± 0.143** | **0.564 ± 0.048** | **0.621 ± 0.047** | **0.542 ± 0.062** | **0.538 ± 0.068** | **0.554 ± 0.048** |

BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab. CPG: clinical practice guidelines

**Table (S2).9: Value estimates, 100-points distribution, managers (n=5), mean ± standard deviation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Criteria | BKZ vs. PBO | BKZ vs. ADA | BKZ vs. UST | BKZ vs. SEC | BKZ vs. IXE | BKZ vs. RIS |
| Need for the intervention | | | | | | |
| Disease severity | 0.054 ± 0.029 | | | | | |
| Size of affected population | 0.020 ± 0.008 | | | | | |
| Unmet needs | 0.053 ± 0.020 | | | | | |
| Outcomes of the intervention | | | | | | |
| Level of clearance | 0.122 ± 0.101 | 0.096 ± 0.081 | 0.093 ± 0.083 | 0.080 ± 0.090 | 0.079 ± 0.091 | 0.082 ± 0.089 |
| Rapidity of clearance | 0.041 ± 0.015 | 0.032 ± 0.016 | 0.033 ± 0.015 | 0.026 ± 0.017 | 0.025 ± 0.018 | 0.031 ± 0.011 |
| Persistence of clearance | 0.089 ± 0.022 | 0.070 ± 0.016 | 0.062 ± 0.012 | 0.058 ± 0.015 | 0.058 ± 0.015 | 0.057 ± 0.011 |
| Safety / tolerability | -0.001 ± 0.050 | 0.027 ± 0.035 | 0.015 ± 0.026 | 0.012 ± 0.036 | 0.012 ± 0.027 | -0.003 ± 0.025 |
| Patient reported outcomes | 0.058 ± 0.022 | 0.039 ± 0.025 | 0.028 ± 0.019 | 0.025 ± 0.028 | 0.017 ± 0.028 | 0.015 ± 0.024 |
| Type of benefit for the intervention | | | | | | |
| Type of therapeutic benefit | 0.055 ± 0.024 | | | | | |
| Consistency of the effect | 0.056 ± 0.034 | 0.039 ± 0.023 | 0.029 ± 0.019 | 0.024 ± 0.016 | 0.017 ± 0.032 | 0.021 ± 0.019 |
| Economic consequences of the intervention | | | | | | |
| Cost of intervention | -0.036 ± 0.028 | -0.020 ± 0.016 | -0.013 ± 0.013 | 0.001 ± 0.003 | -0.006 ± 0.013 | 0.016 ± 0.015 |
| Impact on other direct costs | 0.016 ± 0.013 | 0.008 ± 0.006 | 0.006 ± 0.004 | 0.006 ± 0.004 | 0.006 ± 0.004 | 0.004 ± 0.005 |
| Impact on indirect costs | 0.026 ± 0.024 | 0.010 ± 0.013 | 0.007 ± 0.007 | 0.007 ± 0.007 | 0.007 ± 0.007 | 0.007 ± 0.007 |
| Knowledge about the intervention | | | | | | |
| Quality of evidence | 0.049 ± 0.015 | 0.043 ± 0.017 | 0.043 ± 0.017 | 0.045 ± 0.017 | 0.031 ± 0.024 | 0.031 ± 0.024 |
| Expert consensus / CPG | 0.028 ± 0.013 | 0.013 ± 0.014 | 0.010 ± 0.014 | 0.007 ± 0.012 | 0.004 ± 0.011 | 0.006 ± 0.015 |
| Total | **0.631 ± 0.049** | **0.539 ± 0.080** | **0.495 ± 0.043** | **0.474 ± 0.080** | **0.432 ± 0.104** | **0.451 ± 0.072** |

Managers: healthcare managers, hospital pharmacist, health economist and politician. BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab. CPG: clinical practice guidelines